- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
CCI approves acquisition of stake in Asian Institute of Nephrology and Urology by TPG Growth V SF Markets, Waverly through Asia Healthcare Holdings
New Delhi: The Competition Commission of India (CCI) has approved acquisition of stake in Asian Institute of Nephrology and Urology Private Limited by TPG Growth V SF Markets Pte. Ltd. and Waverly Pte. Ltd. through Asia Healthcare Holdings Pte. Ltd.
The proposed combination relates to (a) the acquisition of fresh Redeemable Preference Shares (New RPS) in Asia Healthcare Holdings Pte. Ltd. (AHH) by TPG Growth V SF Markets Pte. Ltd. (Growth V) and Waverly Pte. Ltd. (Waverly) (Part I), and (b) subsequent acquisition of majority shareholding in Asian Institute of Nephrology and Urology Private Limited (AINU) by AHH (Part II).
Growth V is an investment fund that is ultimately managed and controlled by TPG Inc. (TPG), which is a global, diversified investment firm. TPG is the ultimate holding company of the TPG Group, which operates through multiple strategies including buyout/control situations, growth & technology investing, and impact investing (including climate) across multiple sectors such as financial services, technology, consumer, travel, media, real estate, and healthcare. The TPG Group also has a controlling stake in NewQuest Capital, another private equity investment firm having investments across multiple sectors such as financial services, travel, and real estate.
Waverly is a wholly-owned subsidiary of Lathe Investment Private Limited which is in turn, wholly-owned by GIC (Ventures) Pte Ltd. Waverly is a special purpose vehicle organized as a private limited company in Singapore that is part of a group of investment holding companies managed by GIC Special Investments Private Limited.
AHH is a Singapore incorporated company and is primarily engaged in long-term investment holding activities and through its direct/ indirect subsidiaries, is active in providing healthcare services in the field of maternal, child, and other related healthcare services in India. AHH is jointly owned and controlled by the TPG Group and Waverly.
AINU, as a single-specialty center in South India, focuses on providing healthcare services through hospitals, specializing in (i) urology care, (ii) nephrology care, and (iii) dialysis and kidney transplant. They also provide radiology and pathology services to their patients. It has seven hospitals located across Hyderabad (including Secunderabad), Vishakhapatnam, Siliguri, and Chennai.
Read also: CCI clears Seventy Second Investment stake acquisition in Manipal Health Enterprises
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751